Aflibercept, ranibizumab are not cost effective in DME
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2016 Category: Drugs & Pharmacology Source Type: news
Industry Incentives May Drive Pricier Anti-VEGF Drug UseIndustry Incentives May Drive Pricier Anti-VEGF Drug Use
Ophthalmologists with the most and largest payments had highest rates of injection with aflibercept and ranibizumab. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 23, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Two Expensive Diabetic Macular Edema Drugs Not Cost-effectiveTwo Expensive Diabetic Macular Edema Drugs Not Cost-effective
Anti-VEGF medicines aflibercept and ranibizumab would have to drop in price by 69% and 80%, respectively, to be worth the societal cost compared with bevacizumab, a new study has found. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
High-priced drugs used to treat diabetic macular edema not cost-effective
The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are not cost-effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - June 9, 2016 Category: Science Source Type: news
Newer Drugs Helping Older People With Eye Disease
FRIDAY, May 20, 2016 -- New medications are boosting quality of life for many older people with age-related macular degeneration (AMD), a new study indicates.
The drugs Avastin and Lucentis have significantly increased the number of people with AMD... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 20, 2016 Category: Journals (General) Source Type: news
Long-term benefits of age-related macular degeneration treatments
A 5-year follow-up study confirmed the long-term benefits of using the drugs Avastin and Lucentis to treat age-related macular degeneration. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - May 9, 2016 Category: Consumer Health News Source Type: news
Age-related macular degeneration before and after the era of anti-VEGF drugs
NIH-funded study of Avastin and Lucentis examines their effects at five years. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - May 3, 2016 Category: American Health Source Type: news
Many With Wet AMD Need Ranibizumab Retreatment Even After Year-Long PauseMany With Wet AMD Need Ranibizumab Retreatment Even After Year-Long Pause
Retreatment with ranibizumab is necessary for up to a third of neovascular age-related macular degeneration (AMD) patients who are treatment-free for one year, new research shows. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 27, 2016 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Delayed Visual Improvements in AMD Continue With Ranibizumab TreatmentDelayed Visual Improvements in AMD Continue With Ranibizumab Treatment
Visual improvements in patients with neovascular age-related macular degeneration (AMD) treated with ranibizumab continue after macular edema resolves, researchers report. Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - March 30, 2016 Category: Opthalmology Tags: Ophthalmology News Source Type: news
Aflibercept for Macular Edema Secondary to Central RVOAflibercept for Macular Edema Secondary to Central RVO
Aflibercept may be an effective therapeutic option for macular edema due to central retinal vein occlusion that did not respond to treatment with bevacizumab or ranibizumab. Eye (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2016 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Aflibercept Best in Diabetics With Bad Baseline Vision? Aflibercept Best in Diabetics With Bad Baseline Vision?
Final results from a trial comparing aflibercept, bevacizumab, and ranibizumab in diabetic macular edema confirm all three drugs are similar, but aflibercept is best in those with worse baseline vision, says lead researcher. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 1, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
DME Drugs Equally Effective at 2 Years
(MedPage Today) -- But more adverse events seen with Lucentis versus Eylea (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 29, 2016 Category: Cardiology Source Type: news
Eylea outperforms Avastin for diabetic macular edema with moderate or worse vision loss
NIH-funded clinical trial shows Eylea, Avastin, and Lucentis perform similarly when vision loss is mild. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 29, 2016 Category: American Health Source Type: news
Study Compares Drugs for Common Diabetic Eye Disease
MONDAY, Feb. 29, 2016 -- People with diabetes are at risk for blurred vision or even a loss of vision from a condition called macular edema.
Three drugs for the disease -- Avastin, Eylea and Lucentis -- vary widely in price, but new research... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 29, 2016 Category: Journals (General) Source Type: news
Ranibizumab for the Treatment of Wet AMDRanibizumab for the Treatment of Wet AMD
Ranibizumab for wet AMD has shown success in clinical trials, but are those same results achieved in real-world clinical practice? Eye (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 25, 2016 Category: Opthalmology Tags: Ophthalmology Journal Article Source Type: news
